Proxy firms back BMS in Celgene takeout

Celgene shares rose $6.89 to $94.34 Friday after two influential proxy-advisory firms recommended Bristol-Myers shareholders

Read the full 156 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE